Alvotech's Entyvio Biosimilar Candidate (AVT80) Achieves Positive Pivotal Study Results
Summary
Alvotech announced positive top-line results from a pivotal pharmacokinetic study for AVT80, its biosimilar candidate to the $6.4 billion drug Entyvio, meeting all primary endpoints and paving the way for regulatory submissions.
Key Events
-
Positive Pivotal Study Results
AVT80, a biosimilar candidate to Entyvio (vedolizumab), met all primary endpoints in its pivotal pharmacokinetic study, demonstrating PK similarity, safety, tolerability, and immunogenicity.
-
Path to Regulatory Submissions
The successful study allows Alvotech to advance towards regulatory submissions for both subcutaneous (AVT80) and intravenous (AVT16) formulations of the biosimilar.
-
Targeting a Blockbuster Market
Entyvio, the reference product, generated approximately $6.4 billion in global net revenues in 2025, highlighting the significant market opportunity for Alvotech's biosimilar.
Analysis
This announcement of positive top-line results from a pivotal pharmacokinetic study for AVT80, a biosimilar candidate to Entyvio, significantly de-risks Alvotech's pipeline. Entyvio generated approximately $6.4 billion in global net revenues in 2025, making its biosimilar a potentially major revenue driver for Alvotech. Meeting all primary endpoints in this pivotal study allows the company to proceed towards regulatory submissions for both subcutaneous (AVT80) and intravenous (AVT16) formulations, marking a critical step towards commercialization. This positive development follows a series of recent strategic moves, including a major licensing agreement, significant insider share acquisitions, and a new loan facility, collectively strengthening the company's position.
At the time of this filing, ALVO was trading at $5.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $4.32 to $13.08. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.